Eligibility for cardiac resynchronization therapy was met in 4.0% to 9.3% of patients with transposition of the great arteries and 4.1% to 6.1% of those with congenitally corrected TGA.
Observational (n=124)
AIMS: Patients with a systemic right ventricle (RV) frequently develop heart failure and may benefit from cardiac resynchronization therapy (CRT). We aimed to assess the proportion of unselected patients with a systemic RV eligible for CRT and to review available data on the effect of CRT in congenital heart disease patients. METHODS AND RESULTS: Adhering to criteria derived from landmark CRT trials, we determined the eligibility of patients with a systemic RV for CRT. Seventy-five transposition of the great arteries (TGA) patients (age 29.5+/-10.2 years) and 49 patients with congenitally corrected (cc) TGA (age 36.2+/-12.8 years) were studied. Full criteria for CRT were met in 4.0% of the TGA patients and 4.1% of the ccTGA patients. Including New York Heart Association class 2 patients, 9.3% of TGA and 6.1% of ccTGA patients were eligible for CRT. CONCLUSION: Four to 9% of unselected patients with a systemic RV appear to be potential candidates for CRT. Although large clinical studies are currently lacking, available data consistently demonstrate that CRT improves haemodynamics in congenital heart disease patients and warrants further investigation.
Diller et al. (Sat,) conducted a observational in Adult congenital heart disease with a systemic right ventricle (n=124). Cardiac resynchronization therapy (CRT) eligibility criteria was evaluated on Proportion of patients eligible for CRT based on landmark trial criteria. Eligibility for cardiac resynchronization therapy was met in 4.0% to 9.3% of patients with transposition of the great arteries and 4.1% to 6.1% of those with congenitally corrected TGA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: